Show simple item record

dc.contributor.advisorPeter Hutten_US
dc.contributor.authorSullivan, Katherine
dc.date.accessioned2012-05-19T22:04:17Z
dc.date.issued2011
dc.identifier.citationKatherine Sullivan, IMS Health v. Sorrell – Implications for Federal Regulation of Pharmaceutical Marketing? (2011).en_US
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:8789615
dc.description.abstractABSTRACT In an era of increased scrutiny of laws regulating corporate speech, state and federal regulators must balance regulation of the prescription drug market with the budgetary and public health needs. One area of contention is the use of prescriber data for pharmaceutical marketing. Claiming a need to protect physician privacy and the state budget, Vermont limited access to this data. Pharmaceutical companies and data processors filed suit, claiming a violation of their First Amendment rights. The Supreme Court recently heard the case. The outcome could have broad implications not only for states’ ability to protect privacy but also for FDA’s restrictions on pharmaceutical marketing. If the Supreme Court chooses to invalidate Vermont’s law, FDA’s regulation of off-label promotion could be ripe for a judicial challenge.en_US
dash.licenseLAA
dc.subjecthuman drugs>>prescription drug promotion>>physician advertisingen_US
dc.subject.otherFood and Drug Lawen_US
dc.titleIMS Health v. Sorrell – Implications for Federal Regulation of Pharmaceutical Marketing?en_US
dc.typePaper (for course/seminar/workshop)en_US
dc.date.available2012-05-19T22:04:17Z


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record